BPC-157 vs TB-500
A factual side-by-side from public databases — chemical identity, literature volume, and attributed independent-test coverage. Not a recommendation; we don't rank one above the other.
BPC-157 (body protection compound-157) is described as a stable gastric pentadecapeptide that has been investigated largely in preclinical models for effects related to cytoprotection and tissue repair across multiple organ systems, including musculoskeletal soft tissue and bone injuries. A systematic review from an orthopedic sports medicine perspective identified 36 included studies (35 preclinical, 1 clinical) reporting musculoskeletal improvements in multiple injury types, along with liver metabolism and kidney clearance; it also reported that no clinical safety data were found. (PMIDs: 40756949)
TB-500 (also referred to as TB500; thymosin β4 fragment) is described in the provided literature as a peptide being used/marketed in contexts such as orthopaedics/sports medicine and as a doping-relevant compound. Narrative reviews report that evidence for clinical benefit in musculoskeletal outcomes is limited, with many findings largely based on preclinical work. Multiple studies focus on analytical detection of TB-500 (and its thymosin β4–derived segment) in equine and human doping-control settings.
| BPC-157 | TB-500 | |
|---|---|---|
| Family | Repair & thymosin peptides | Repair & thymosin peptides |
| Research goals | Recovery & tissue repair | Recovery & tissue repair |
| Amino acids | — | — |
| Molecular formula | C62H98N16O22 | C38H68N10O14 |
| Molecular weight | 1419.5 g/mol | 889 g/mol |
| CAS number | 137525-51-0 | 885340-08-9 |
| Approx. half-life | — | — |
| Regulatory status | Research only | Research only |
| WADA status | — | — |
| Evidence maturity | — | — |
| Research references | 8 | 8 |